Who we are
ABOUT MEDICINES FOR EUROPE
PURPOSE AND OBJECTIVES
OUR VALUES – OUR 5 PILLARS
STRUCTURE
MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
Vacancies
Manifesto 2024
Key topics
ACCESS
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
SUSTAINABILITY
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
EXTERNAL RESOURCES
FACTSHEETS
INFOGRAPHICS
PODCAST
POLICY
REPORTS
VIDEOS
Newsroom
IN THE NEWS
PRESS RELEASES
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Publications
Filters:
policy
x
By group
By type
External Resources
Factsheets
Infographics
PODCAST
Policy
Reports
Videos
Newsroom
Twitter
Tweets
Videos
Photos
5-Point Pharmaceutical Action Plan to Sustain Investment in Europe, for Europe
10 April 2025
Policy
Read More
Note on Proposals to Extend Pharmaceutical Intellectual Property Incentives in reaction to U.S. Tariffs
10 April 2025
Policy
Read More
The Severe Impacts of Potential U.S. Tariffs on Pharmaceuticals
8 April 2025
Policy
Read More
European Parliament Hearing on the Overreliance on Imports of Active Pharmaceutical Ingredients (APIs)
5 March 2025
Policy
Read More
Proposals to Accelerate the EU Integration of the Ukrainian Pharmaceutical Industry
4 February 2025
Policy
Read More
Position Papers on Electronic Product Information (ePI)
8 January 2025
Policy
Read More
Position Paper on the Overreliance on imports of Active Pharmaceutical Ingredients (APIs)
27 September 2024
Policy
Read More
Review of the SPC Manufacturing Waiver: a 2024 Industry Report
10 June 2024
Policy
Read More
Medicines shortages and national stockpiling requirements in the EU – Position Paper
15 April 2024
Policy
Read More
Impact of extending the duration of regulatory data protection in the new EU pharmaceutical legislation
14 February 2024
Policy
Read More
Posts navigation
1
2
3
…
9
Subscribe to our newsletter
[contact-form-7 id="1638" title="Newsletter subscription"]
Medicines For Europe
Who we are
Vacancies
Manifesto 2024
Key topics – COVID-19
Publications
Newsroom
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Share This
LinkedIn
Share on Mastodon
Enter your Mastodon instance URL (optional)
Share
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
